Drug Trial Radar · NCT06762548
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 10, 2027
Primary completion
Mar 11, 2028
Study completion Nov 6, 2028
Sponsor
- Lead sponsor
- Applied Biology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Daniel Alain, Inc.; Follea International Limited
- First posted
- Jan 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia
Conditions
- Chemotherapy Induced Alopecia
- Chemotherapy Side Effects
Interventions
DA-007Drug
Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine
PlaceboDrug
Topical placebo solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevention of Hair Loss (Common Terminology Criteria for Adverse Events V5.0)Time frame: Week [0,12]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Rome ("G. Marconi")
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.